CAH
Cardinal Health IncHealth Careinsider_universeEverything we've seen
- ·Sep 11, 6:04 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 6:04 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 6:04 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 6:04 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 6:04 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 5:49 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 5:49 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 5:49 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 5:49 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 5:49 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 5:34 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 5:34 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 5:34 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 5:34 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 5:34 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 5:19 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 5:19 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 5:19 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 5:19 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 5:19 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 5:04 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 5:04 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 5:04 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 5:04 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 5:04 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 4:49 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 4:49 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 4:49 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 4:49 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 4:49 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 4:35 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 4:35 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 4:35 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 4:35 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 4:35 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 4:19 PMstreamnews
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ·Sep 11, 4:19 PMstreamnews
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ·Sep 11, 4:19 PMstreamnews
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ·Sep 11, 4:19 PMstreamnews
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ·Sep 11, 4:19 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ·Sep 11, 4:19 PMstreamnews
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
- ·Sep 11, 4:04 PMstreamnews
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ❖Sep 11, 2:21 PMnewsvia finnhub
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
- ❖Sep 11, 11:49 AMnewsvia finnhub
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
- ❖Sep 11, 11:29 AMnewsvia finnhub
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
- ▣Sep 10, 8:00 PMjournaltime_stop
Agent 20 — SIR Price/Volume closed long 9 @ $234.57 (+$164.43)
Time stop: held 92 ≥ 90 days
- ❖Sep 10, 1:46 PMnewsvia finnhub
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
- ❖Sep 10, 12:21 PMnewsvia finnhub
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
- ❖Sep 10, 11:30 AMnewsvia finnhub
Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- ❖Sep 9, 3:12 PMnewsvia finnhub
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ❖Sep 9, 6:57 AMnewsvia finnhub
Cardinal Health, Inc. (CAH) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cardinal Health, Inc. (CAH) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:45 AM EDTCompany ParticipantsDavid Frost - Vice President of...
- ❖Sep 8, 6:00 PMnewsvia finnhub
Cardinal Health (CAH) Declines More Than Market: Some Information for Investors
In the latest trading session, Cardinal Health (CAH) closed at $240.49, marking a -2.71% move from the previous day.
- ❖Sep 8, 11:07 AMnewsvia finnhub
Is Cardinal Health Building a New Tech-Enabled Healthcare Platform?
Technology is becoming a bigger part of CAH's strategy, linking distribution, specialty services and logistics through digital workflows.
- ?Sep 8, 10:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is down 2.04% with ~295 minutes remaining, which is a meaningful intraday move suggesting real selling flow with institutional conviction. No headlines are available to explain the move, but absence of news is not disqualifying — this magnitude of decline reflects genuine distribution. The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which is modestly headwind for rate-sensitive and defensive healthcare/distribution names like CAH (Cardinal Health is a healthcare distributor with stable but bond-proxy characteristics). Elevated inflation expectations can pressure such names as discount rates rise. However, several factors temper conviction: (1) no news catalyst means we cannot confirm whether this is a sustained theme or a block-driven idiosyncratic flush that may have already exhausted itself; (2) with nearly 5 hours remaining, there is ample time for either continuation or mean reversion — more time is generally neutral here; (3) the macro signal is indirect and not a strong sector-specific driver. On balance, there is mild evidence of continued downward pressure from macro context and the initial momentum, but no strong reason to call a reversal either. Assigning a slight lean toward continuation at the lower bound of the momentum range.
- !Sep 8, 10:50 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is down 2.04% with ~295 minutes remaining, which is a meaningful intraday move suggesting real selling flow with institutional conviction. No headlines are available to explain the move, but absence of news is not disqualifying — this magnitude of decline reflects genuine distribution. The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which is modestly headwind for rate-sensitive and defensive healthcare/distribution names like CAH (Cardinal Health is a healthcare distributor with stable but bond-proxy characteristics). Elevated inflation expectations can pressure such names as discount rates rise. However, several factors temper conviction: (1) no news catalyst means we cannot confirm whether this is a sustained theme or a block-driven idiosyncratic flush that may have already exhausted itself; (2) with nearly 5 hours remaining, there is ample time for either continuation or mean reversion — more time is generally neutral here; (3) the macro signal is indirect and not a strong sector-specific driver. On balance, there is mild evidence of continued downward pressure from macro context and the initial momentum, but no strong reason to call a reversal either. Assigning a slight lean toward continuation at the lower bound of the momentum range.
- ❖Sep 8, 9:02 AMnewsvia finnhub
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id
- ❖Sep 4, 2:50 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
- ❖Sep 3, 5:52 PMnewsvia finnhub
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
- ❖Sep 3, 3:22 PMnewsvia finnhub
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
- ❖Sep 3, 9:22 AMnewsvia finnhub
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
- ❖Sep 2, 12:36 PMnewsvia finnhub
Silchester International Investors - Press Release and EGM Demand Letter - Medipal Holdings Corporation (7459:JT)
Since April 2026, Silchester has had a number of discussions with the Company. Silchester has come to hold serious concerns about the Company's fundamental attitude toward its shareholders. Accordingly, on 2 September 2026, Silchester formally demanded, pursuant to Article 297, Paragraph 1 of the Companies Act, that the Company convene an extraordinary general meeting of shareholders (the "EGM") to consider the four proposals summarised below. Silchester has asked that the EGM be held no later t
- ?Sep 2, 11:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 2.48% today with no directly attributable headline catalyst visible, suggesting institutional flow or sector rotation is driving the move rather than a news event that could reverse on detail. The healthcare distribution space (peers like Cencora mentioned in headlines) shows some sector activity today. However, macro context is mildly headwind: the 5Y forward inflation rate is elevated at 1.7σ above trend, which can pressure rate-sensitive and defensive healthcare names at the margin as it raises discount rates. With 235 minutes remaining (nearly a full session left), there is ample time for continuation but also for mean reversion if this is an overextension. The move at 2.48% is meaningful but sits at the lower bound of the 2-5% conviction range. No reversal pattern is evident from the data provided, and the absence of a specific news catalyst cuts both ways — no catalyst to fade, but also no fundamental anchor supporting further extension. Overall, momentum is modestly in favor of continuation with no strong reason to expect a fade, warranting a slight lean toward up continuation at the lower end of the ordinary momentum range.
- !Sep 2, 11:51 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 2.48% today with no directly attributable headline catalyst visible, suggesting institutional flow or sector rotation is driving the move rather than a news event that could reverse on detail. The healthcare distribution space (peers like Cencora mentioned in headlines) shows some sector activity today. However, macro context is mildly headwind: the 5Y forward inflation rate is elevated at 1.7σ above trend, which can pressure rate-sensitive and defensive healthcare names at the margin as it raises discount rates. With 235 minutes remaining (nearly a full session left), there is ample time for continuation but also for mean reversion if this is an overextension. The move at 2.48% is meaningful but sits at the lower bound of the 2-5% conviction range. No reversal pattern is evident from the data provided, and the absence of a specific news catalyst cuts both ways — no catalyst to fade, but also no fundamental anchor supporting further extension. Overall, momentum is modestly in favor of continuation with no strong reason to expect a fade, warranting a slight lean toward up continuation at the lower end of the ordinary momentum range.
- ❖Sep 2, 10:40 AMnewsvia finnhub
Is Henry Schein (HSIC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- ?Sep 2, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.62% today, a modest but meaningful move indicating real buying flow. There is no directly attributable news catalyst for CAH (the only headline references HSIC, a competitor, and is mildly positive for sector sentiment at best). Macro context shows 5Y5Y forward inflation running 1.7σ above trend, which is a mild headwind for rate-sensitive sectors, but healthcare distributors like CAH are not highly rate-sensitive and this is not a strong disqualifier. With 355 minutes remaining (effectively a full remaining session), there is ample time for continuation. The move magnitude at 1.62% is real but not extreme, suggesting momentum that has not exhausted itself. No reversal signals are evident from the data provided. In the absence of a fade catalyst, the default lean per framework is continuation. Probability is kept at the lower end of the ordinary-momentum range given the lack of a confirming catalyst and the mildly unfavorable macro backdrop for rate-sensitive names.
- !Sep 2, 9:50 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 1.62% today, a modest but meaningful move indicating real buying flow. There is no directly attributable news catalyst for CAH (the only headline references HSIC, a competitor, and is mildly positive for sector sentiment at best). Macro context shows 5Y5Y forward inflation running 1.7σ above trend, which is a mild headwind for rate-sensitive sectors, but healthcare distributors like CAH are not highly rate-sensitive and this is not a strong disqualifier. With 355 minutes remaining (effectively a full remaining session), there is ample time for continuation. The move magnitude at 1.62% is real but not extreme, suggesting momentum that has not exhausted itself. No reversal signals are evident from the data provided. In the absence of a fade catalyst, the default lean per framework is continuation. Probability is kept at the lower end of the ordinary-momentum range given the lack of a confirming catalyst and the mildly unfavorable macro backdrop for rate-sensitive names.
- ❖Sep 2, 9:39 AMnewsvia finnhub
Here's How CVS' Improving Balance Sheet Supports Deleveraging
CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.
- ❖Sep 2, 9:30 AMnewsvia finnhub
Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.
- ❖Sep 2, 7:51 AMnewsvia finnhub
McKesson confirms data theft in cyberattack involving third-party apps
The healthcare distributor said the incident affected a subset of customers in its oncology and medical-surgical businesses.
- ❖Sep 1, 8:07 PMnewsvia finnhub
Henry Schein (HSIC) Looks Modestly Undervalued, Is More Upside Still Available?
Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...
- ?Sep 1, 11:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 2.00% today with 240 minutes remaining — ample time for continuation into the close. The move is meaningful and suggests real institutional flow. However, there is no identifiable catalyst specific to CAH driving the move; the only headline is an unrelated FocalTherics conference presentation. The macro backdrop shows elevated 2Y rates (4.34, +2.0σ above trend), which is a mild headwind for healthcare distributors via discount rate pressure but not a direct sector driver. CAH is a defensive, non-rate-sensitive name in distribution/healthcare logistics, so the macro factor is largely neutral here. With no clear catalyst and no reversal signal visible, the default lean is mild continuation — the move reflects real buying pressure and there is no strong reason to expect a fade. Probability sits at the lower end of the continuation range given the absence of a confirmable news driver and the lack of sector tailwinds today.
- !Sep 1, 11:46 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 2.00% today with 240 minutes remaining — ample time for continuation into the close. The move is meaningful and suggests real institutional flow. However, there is no identifiable catalyst specific to CAH driving the move; the only headline is an unrelated FocalTherics conference presentation. The macro backdrop shows elevated 2Y rates (4.34, +2.0σ above trend), which is a mild headwind for healthcare distributors via discount rate pressure but not a direct sector driver. CAH is a defensive, non-rate-sensitive name in distribution/healthcare logistics, so the macro factor is largely neutral here. With no clear catalyst and no reversal signal visible, the default lean is mild continuation — the move reflects real buying pressure and there is no strong reason to expect a fade. Probability sits at the lower end of the continuation range given the absence of a confirmable news driver and the lack of sector tailwinds today.
- ?Sep 1, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 2.28% intraday with 350 minutes remaining (early in the session), providing ample time for continuation. The move is meaningful in size, suggesting real institutional flow. No news is present, which is common for CAH given it is a healthcare distribution company that often moves on sector rotation or fund flows rather than headlines. The macro context shows elevated 2Y rates (4.34, +2.0σ above trend), which is modestly negative for rate-sensitive sectors but healthcare distribution is relatively insulated — CAH's business model is not duration-sensitive. No reversal signals are apparent from the data provided. With no contra-indicators and a solid intraday move early in the session, ordinary momentum logic favors modest continuation into the close. Probability is held at the lower end of the continuation range due to the absence of a clear catalyst or sector tailwind to sustain the move aggressively.
- !Sep 1, 9:55 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 2.28% intraday with 350 minutes remaining (early in the session), providing ample time for continuation. The move is meaningful in size, suggesting real institutional flow. No news is present, which is common for CAH given it is a healthcare distribution company that often moves on sector rotation or fund flows rather than headlines. The macro context shows elevated 2Y rates (4.34, +2.0σ above trend), which is modestly negative for rate-sensitive sectors but healthcare distribution is relatively insulated — CAH's business model is not duration-sensitive. No reversal signals are apparent from the data provided. With no contra-indicators and a solid intraday move early in the session, ordinary momentum logic favors modest continuation into the close. Probability is held at the lower end of the continuation range due to the absence of a clear catalyst or sector tailwind to sustain the move aggressively.
- ❖Sep 1, 8:30 AMnewsvia finnhub
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026 FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026 AUSTIN, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that Ryan Rhodes, Chief Executive Officer, is schedul
- ❖Aug 31, 12:01 PMnewsvia finnhub
Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis
MD Sass, a boutique asset management firm, published its second-quarter investor update for its flagship, the “MD Sass Concentrated Value Strategy.” The letter can be downloaded here. In the first half of 2026, AI infrastructure stocks led the market, with the Russell 1000 Value increasing by 16.3%, outpacing the S&P 500 (10.2%) and Russell 1000 […]
- ?Aug 25, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.52% with only 10 minutes remaining until the forced 3:45 PM ET close. The move is modest — below the 2% threshold where conviction is clearly established — and with essentially no time remaining, there is minimal runway for continuation even if momentum is intact. No headlines provide a catalyst to sustain the move. The macro context (5Y5Y inflation forward 1.8σ above trend) is a mild headwind for rate-sensitive sectors, and CAH as a healthcare distributor is not directly rate-sensitive, but the elevated inflation expectations create a generally cautious backdrop. At 10 minutes to cutoff, even a clean momentum setup offers little time to reach the +3% profit target from current levels (+1.48% more needed), and the risk of end-of-day profit-taking or mean reversion in the final minutes outweighs the continuation case. Probability falls just below the 0.5 trigger threshold primarily due to the extreme time constraint.
- !Aug 25, 3:35 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 1.52% with only 10 minutes remaining until the forced 3:45 PM ET close. The move is modest — below the 2% threshold where conviction is clearly established — and with essentially no time remaining, there is minimal runway for continuation even if momentum is intact. No headlines provide a catalyst to sustain the move. The macro context (5Y5Y inflation forward 1.8σ above trend) is a mild headwind for rate-sensitive sectors, and CAH as a healthcare distributor is not directly rate-sensitive, but the elevated inflation expectations create a generally cautious backdrop. At 10 minutes to cutoff, even a clean momentum setup offers little time to reach the +3% profit target from current levels (+1.48% more needed), and the risk of end-of-day profit-taking or mean reversion in the final minutes outweighs the continuation case. Probability falls just below the 0.5 trigger threshold primarily due to the extreme time constraint.
- ?Aug 24, 4:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH's 10.2% dip from its 30-day high follows a strong earnings report that sent shares to record highs (per the August 22 headline), with the decline driven primarily by a wave of coordinated insider selling — CEO, CFO, CIO, General Counsel, and two segment heads all filing transactions on August 22-23, totaling tens of millions in stock sales. This is a meaningful negative signal on a dip: insiders who just saw shares hit record highs are distributing aggressively, suggesting they view the current price as full or rich. The underlying business appears fundamentally sound (healthcare distribution, defensive sector), and the recent earnings beat supports that view. However, the options flow is bearish (P/C ratio of 3.0, put volume at z=+1.68), and the insider selling cluster is a clear risk discount. The re-entry context is relevant: the prior stop-out at $220.48 was profitable, and the stock has recovered well above that level, but the current dip is not driven by a fundamental overreaction — it's a post-record-high profit-taking event with insider participation, which limits large-rebound potential from here.
- !Aug 24, 4:24 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CAH's 10.2% dip from its 30-day high follows a strong earnings report that sent shares to record highs (per the August 22 headline), with the decline driven primarily by a wave of coordinated insider selling — CEO, CFO, CIO, General Counsel, and two segment heads all filing transactions on August 22-23, totaling tens of millions in stock sales. This is a meaningful negative signal on a dip: insiders who just saw shares hit record highs are distributing aggressively, suggesting they view the current price as full or rich. The underlying business appears fundamentally sound (healthcare distribution, defensive sector), and the recent earnings beat supports that view. However, the options flow is bearish (P/C ratio of 3.0, put volume at z=+1.68), and the insider selling cluster is a clear risk discount. The re-entry context is relevant: the prior stop-out at $220.48 was profitable, and the stock has recovered well above that level, but the current dip is not driven by a fundamental overreaction — it's a post-record-high profit-taking event with insider participation, which limits large-rebound potential from here.
- ?Aug 24, 4:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
Net signal score: -1. CAH is down 10.2% from its 30-day high — below the +1 threshold of >=15% — so no mean-reversion bonus applies. No hard veto fires: earnings are 65 days away, the 10-K/8-K filings show no disclosed fundamental deterioration, and the drop is only 10.2%. However, the signal stack is net negative: (1) Options flow is strongly bearish with a put/call ratio of 3.00 and put z-score of +1.68, consistent with informed downside hedging (-1 for unusual put volume). (2) The 10Y yield at 4.65% is above the ~4.5% threshold, a mild structural headwind for a defensive healthcare distributor (-1 for high rates, though partially offset by CAH's value/defensive character, scored conservatively at -0.5). (3) Insider activity on 2026-08-22/23 shows clustered multi-executive sales including the CEO selling $29M, CFO ~$9.9M, Medical Segment head ~$8M, Pharma Chief, CIO, and Legal Chief — a broad insider selling cluster, which is a meaningful negative signal (-1). Partial offsets: earnings runway is clean at 65 days (+1), macro VIX is at the 6th percentile (very low fear, neutral-to-positive, +0.5), and Health Care sector ranks 4th of 11 by 30d relative strength with a mild 5d outperformance vs SPY (+0.5). Net score approximates -1, pulling the base rate of ~57% down to approximately 0.48.
- !Aug 24, 4:24 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
Net signal score: -1. CAH is down 10.2% from its 30-day high — below the +1 threshold of >=15% — so no mean-reversion bonus applies. No hard veto fires: earnings are 65 days away, the 10-K/8-K filings show no disclosed fundamental deterioration, and the drop is only 10.2%. However, the signal stack is net negative: (1) Options flow is strongly bearish with a put/call ratio of 3.00 and put z-score of +1.68, consistent with informed downside hedging (-1 for unusual put volume). (2) The 10Y yield at 4.65% is above the ~4.5% threshold, a mild structural headwind for a defensive healthcare distributor (-1 for high rates, though partially offset by CAH's value/defensive character, scored conservatively at -0.5). (3) Insider activity on 2026-08-22/23 shows clustered multi-executive sales including the CEO selling $29M, CFO ~$9.9M, Medical Segment head ~$8M, Pharma Chief, CIO, and Legal Chief — a broad insider selling cluster, which is a meaningful negative signal (-1). Partial offsets: earnings runway is clean at 65 days (+1), macro VIX is at the 6th percentile (very low fear, neutral-to-positive, +0.5), and Health Care sector ranks 4th of 11 by 30d relative strength with a mild 5d outperformance vs SPY (+0.5). Net score approximates -1, pulling the base rate of ~57% down to approximately 0.48.
- ?Aug 24, 12:16 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
Net signal score: -1. CAH is down 10.2% from its 30-day high — below the +1 threshold of >=15% — so no mean-reversion bonus applies. No hard veto fires: earnings are 65 days away, the 10-K/8-K filings show no disclosed fundamental deterioration, and the drop is only 10.2%. However, the signal stack is net negative: (1) Options flow is strongly bearish with a put/call ratio of 3.00 and put z-score of +1.68, consistent with informed downside hedging (-1 for unusual put volume). (2) The 10Y yield at 4.65% is above the ~4.5% threshold, a mild structural headwind for a defensive healthcare distributor (-1 for high rates, though partially offset by CAH's value/defensive character, scored conservatively at -0.5). (3) Insider activity on 2026-08-22/23 shows clustered multi-executive sales including the CEO selling $29M, CFO ~$9.9M, Medical Segment head ~$8M, Pharma Chief, CIO, and Legal Chief — a broad insider selling cluster, which is a meaningful negative signal (-1). Partial offsets: earnings runway is clean at 65 days (+1), macro VIX is at the 6th percentile (very low fear, neutral-to-positive, +0.5), and Health Care sector ranks 4th of 11 by 30d relative strength with a mild 5d outperformance vs SPY (+0.5). Net score approximates -1, pulling the base rate of ~57% down to approximately 0.48.
- !Aug 24, 12:16 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
Net signal score: -1. CAH is down 10.2% from its 30-day high — below the +1 threshold of >=15% — so no mean-reversion bonus applies. No hard veto fires: earnings are 65 days away, the 10-K/8-K filings show no disclosed fundamental deterioration, and the drop is only 10.2%. However, the signal stack is net negative: (1) Options flow is strongly bearish with a put/call ratio of 3.00 and put z-score of +1.68, consistent with informed downside hedging (-1 for unusual put volume). (2) The 10Y yield at 4.65% is above the ~4.5% threshold, a mild structural headwind for a defensive healthcare distributor (-1 for high rates, though partially offset by CAH's value/defensive character, scored conservatively at -0.5). (3) Insider activity on 2026-08-22/23 shows clustered multi-executive sales including the CEO selling $29M, CFO ~$9.9M, Medical Segment head ~$8M, Pharma Chief, CIO, and Legal Chief — a broad insider selling cluster, which is a meaningful negative signal (-1). Partial offsets: earnings runway is clean at 65 days (+1), macro VIX is at the 6th percentile (very low fear, neutral-to-positive, +0.5), and Health Care sector ranks 4th of 11 by 30d relative strength with a mild 5d outperformance vs SPY (+0.5). Net score approximates -1, pulling the base rate of ~57% down to approximately 0.48.
- ?Aug 24, 12:16 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH's 10.2% dip from its 30-day high follows a strong earnings report that sent shares to record highs (per the August 22 headline), with the decline driven primarily by a wave of coordinated insider selling — CEO, CFO, CIO, General Counsel, and two segment heads all filing transactions on August 22-23, totaling tens of millions in stock sales. This is a meaningful negative signal on a dip: insiders who just saw shares hit record highs are distributing aggressively, suggesting they view the current price as full or rich. The underlying business appears fundamentally sound (healthcare distribution, defensive sector), and the recent earnings beat supports that view. However, the options flow is bearish (P/C ratio of 3.0, put volume at z=+1.68), and the insider selling cluster is a clear risk discount. The re-entry context is relevant: the prior stop-out at $220.48 was profitable, and the stock has recovered well above that level, but the current dip is not driven by a fundamental overreaction — it's a post-record-high profit-taking event with insider participation, which limits large-rebound potential from here.
- !Aug 24, 12:16 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CAH's 10.2% dip from its 30-day high follows a strong earnings report that sent shares to record highs (per the August 22 headline), with the decline driven primarily by a wave of coordinated insider selling — CEO, CFO, CIO, General Counsel, and two segment heads all filing transactions on August 22-23, totaling tens of millions in stock sales. This is a meaningful negative signal on a dip: insiders who just saw shares hit record highs are distributing aggressively, suggesting they view the current price as full or rich. The underlying business appears fundamentally sound (healthcare distribution, defensive sector), and the recent earnings beat supports that view. However, the options flow is bearish (P/C ratio of 3.0, put volume at z=+1.68), and the insider selling cluster is a clear risk discount. The re-entry context is relevant: the prior stop-out at $220.48 was profitable, and the stock has recovered well above that level, but the current dip is not driven by a fundamental overreaction — it's a post-record-high profit-taking event with insider participation, which limits large-rebound potential from here.
- ▣Aug 23, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 12 @ $231.00 (-$170.16)
Long stop: close $231.00 ≤ stop $241.50
- ❖Aug 23, 8:58 AMnewsvia finnhub
What to Know About the Latest Sale From Cardinal Health's Chief Accounting Officer
Mary C. Scherer reduced her direct equity but retains 2,811 shares after the stock delivered a 58% return over the past year.
- ❖Aug 23, 8:51 AMnewsvia finnhub
Cardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know
Alt divested part of his direct equity stake after the stock surged 57% over the past year, retaining 20,495 shares worth $4.82 million.
- ❖Aug 23, 8:42 AMnewsvia finnhub
Cardinal Health's Medical Segment Boss Sold $8 Million in Stock. Here's What to Know
This insider sale cut an equity stake following a strong 57% one-year stock run, leaving $4.2 million in direct holdings.
- ❖Aug 23, 8:34 AMnewsvia finnhub
Cardinal Health's Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here's How That Happened
Weitzman's equity reduction follows a 57% one-year stock price surge, leaving her with $18.3 million in direct holdings.
- ❖Aug 23, 8:27 AMnewsvia finnhub
The CIO of Cardinal Health Parted With 11,650 Shares. Here's Whether It Matters for Long-Term Investors
Michelle Greene reduced her direct equity stake following strong stock appreciation, retaining 10,330 shares worth $2.43 million.
- ❖Aug 23, 8:14 AMnewsvia finnhub
Cardinal Health's Legal Chief Just Filed an Insider Transaction. Here's What to Know
Jessica Mayer holds 33,076 shares valued at $7.77 million.
- ❖Aug 23, 7:44 AMnewsvia finnhub
Cardinal Health's CEO Moved 124,529 Shares in Two Days. Here's What Long-Term Investors Should Know
Hollar divested 125,000 shares across two trading sessions, reducing his direct holdings following a 58% one-year stock surge.
- ❖Aug 21, 8:44 PMnewsvia finnhub
Cardinal Health CEO Sells $29 Million in Stock After Earnings Send Shares to Record
CEO Jason Hollar leads a wave of insider selling that saw top executives liquidate nearly $60 million worth of company stock.
- ✓Aug 11, 10:05 AMdecisionacted
Agent 7 — Day Trader — decide: buy
CAH is up 3.37% on earnings call presentation day (Q4 2026 results), which is a clear fundamental catalyst explaining the move. Earnings-driven gaps in healthcare distributors tend to hold and grind higher through the session as institutional investors digest results and initiate or add to positions — fading an earnings beat gap is typically a lower-probability trade. With 340 minutes remaining (essentially a full trading session from here), there is ample time for continuation. The macro context shows 5Y5Y inflation forward running 1.6σ above trend, which is modestly unfavorable for rate-sensitive names, but CAH as a healthcare distributor/services company has limited direct rate sensitivity relative to REITs or utilities — this is a mild headwind at most. No reversal signal is noted; the move appears to be trending rather than fading. Volume on earnings days is typically elevated, supporting price discovery rather than thin-market drift. Overall, a moderate continuation probability is warranted: the catalyst is real, time is ample, and the risk/reward with a 1.5% stop and 3% target is favorable.
- ❖Aug 11, 5:01 AMnewsvia finnhub
Cardinal Health, Inc. 2026 Q4 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Cardinal Health, Inc.
- ▢Aug 10, 8:00 PMjournal
Agent 7 — Day Trader opened long 12 @ $245.18
- ❖Aug 10, 1:29 PMnewsvia finnhub
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
- ❖Aug 10, 1:27 PMnewsvia finnhub
Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline
ITGR beats Q2 earnings and revenue estimates, but sales and margins decrease as product headwinds persist ahead of its $5.7B KKR deal.
- ❖Aug 10, 12:54 PMnewsvia finnhub
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
- ❖Aug 10, 12:37 PMnewsvia finnhub
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
- ❖Aug 10, 11:31 AMnewsvia finnhub
Lumentum Could Swing $9.74 Billion After Earnings
Earnings set to hit the tape Tues. Options market implying post-print swings for 5 stocks, from healthcare to AI. Cardinal Health has biggest move at 6.83%.
- ❖Aug 8, 11:11 PMnewsvia finnhub
Wall Street Week Ahead
Get ready for the week ahead: July CPI/PPI, retail sales, 13F filings, and key earnings (AMAT, CSCO).
- ❖Aug 8, 7:00 AMnewsvia finnhub
Cisco, Tencent Headline Muted Earnings Week
Wall Street Week Ahead: key market events, CPI/retail data, earnings (Cisco, Tencent), IPOs & dividends after weak jobs report. See more details here.
- ❖Aug 7, 4:44 PMnewsvia finnhub
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
- ❖Aug 7, 2:35 PMnewsvia finnhub
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
- ❖Aug 7, 2:20 PMnewsvia finnhub
Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?
Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
- ❖Aug 7, 1:57 PMnewsvia finnhub
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.
- ❖Aug 7, 1:55 PMnewsvia finnhub
Rigetti Q2 Earnings Miss Estimates on Higher Costs, Revenue Beat
RGTI's Q2 revenues surge 185.3% and beat estimates, but widening losses and higher R&D and SG&A costs continue to pressure profitability.
- ❖Aug 7, 12:47 PMnewsvia finnhub
AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up
AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.
- ❖Aug 7, 12:36 PMnewsvia finnhub
DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up
Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.
- ❖Aug 7, 11:14 AMnewsvia finnhub
Does Cardinal Health’s New CAO and Recalls Reveal Shifts in Its Risk Profile and Earnings Quality (CAH)?
In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...
- ❖Aug 7, 11:14 AMnewsvia finnhub
Are Wall Street Analysts Bullish on Cardinal Health Stock?
As Cardinal Health has outpaced relative to the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook about the stock’s prospects.
- ❖Aug 7, 9:40 AMnewsvia finnhub
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- ❖Aug 7, 9:15 AMnewsvia finnhub
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- ▣Jul 21, 8:00 PMjournaltarget
Agent 8 — Dip Buyer (Peer-Aware) closed long 5 @ $220.48 (+$96.68)
Trailing stop on remainder: close $220.48 ≤ floor $222.93 (peak $239.71 × 0.93; floor at entry $201.14)
- ?Jul 17, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.58% today with no attributable headline — this is a modest but real move suggesting some institutional flow. The magnitude is below the 2-5% 'high conviction' threshold, so it reads more as quiet accumulation or sector rotation than a strong catalyst-driven surge. Macro context shows 10Y inflation expectations (T10YIE) running 1.6σ below trend at 2.22, which is modestly supportive for healthcare/distribution names like CAH as a defensive play — lower inflation expectations can favor stable cash-flow businesses. With 320 minutes remaining (a full trading session essentially), there is ample time for the move to extend if buying pressure persists. No reversal signals or fade patterns are indicated. However, the move is not large enough to indicate overwhelming conviction, and no news catalyst is present to sustain a narrative-driven push. Default to mild continuation given bounded downside risk, time remaining, and no specific reason to expect a fade.
- !Jul 17, 10:25 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is up 1.58% today with no attributable headline — this is a modest but real move suggesting some institutional flow. The magnitude is below the 2-5% 'high conviction' threshold, so it reads more as quiet accumulation or sector rotation than a strong catalyst-driven surge. Macro context shows 10Y inflation expectations (T10YIE) running 1.6σ below trend at 2.22, which is modestly supportive for healthcare/distribution names like CAH as a defensive play — lower inflation expectations can favor stable cash-flow businesses. With 320 minutes remaining (a full trading session essentially), there is ample time for the move to extend if buying pressure persists. No reversal signals or fade patterns are indicated. However, the move is not large enough to indicate overwhelming conviction, and no news catalyst is present to sustain a narrative-driven push. Default to mild continuation given bounded downside risk, time remaining, and no specific reason to expect a fade.
- ?Jul 14, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is down 2.23% with only 25 minutes remaining until the forced close. The headline from 13:20 ET explicitly characterizes CAH as 'overvalued following fresh earnings beat hopes,' which is a direct bearish catalyst and explains the selling pressure. However, several factors cut against continuation: (1) Only 25 minutes remain — very limited runway for further downside to develop, and late-session mean reversion or short-covering into the close is common after a move of this magnitude; (2) The move is already -2.23%, approaching the lower bound of a 2-5% meaningful move range, meaning a significant portion of the valuation-reset selling may already be complete; (3) The macro backdrop (T10Y2Y at 1.9σ below trend, bear-flattening) is modestly supportive of defensive names like CAH, not hostile — this could temper further selling; (4) With a tight 25-minute window and the stock already repriced meaningfully, risk/reward for chasing the down move is compressed. The setup does not clear the 0.5 threshold given the time constraint and potential for end-of-day covering.
- !Jul 14, 3:20 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is down 2.23% with only 25 minutes remaining until the forced close. The headline from 13:20 ET explicitly characterizes CAH as 'overvalued following fresh earnings beat hopes,' which is a direct bearish catalyst and explains the selling pressure. However, several factors cut against continuation: (1) Only 25 minutes remain — very limited runway for further downside to develop, and late-session mean reversion or short-covering into the close is common after a move of this magnitude; (2) The move is already -2.23%, approaching the lower bound of a 2-5% meaningful move range, meaning a significant portion of the valuation-reset selling may already be complete; (3) The macro backdrop (T10Y2Y at 1.9σ below trend, bear-flattening) is modestly supportive of defensive names like CAH, not hostile — this could temper further selling; (4) With a tight 25-minute window and the stock already repriced meaningfully, risk/reward for chasing the down move is compressed. The setup does not clear the 0.5 threshold given the time constraint and potential for end-of-day covering.
- ?Jul 14, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is down 1.66% today, a meaningful but not extreme move. The only headline is a generic Zacks industry outlook piece covering multiple healthcare distributors including Cardinal Health — no company-specific catalyst is evident, making this more likely flow/sector rotation than news-driven. The macro context shows a flattening yield curve (T10Y2Y 1.9σ below trend), which is modestly supportive of defensives like healthcare distributors, creating a mild headwind against further downside continuation. With 355 minutes remaining there is ample time for the move to extend, but the lack of a clear negative catalyst and the defensive sector tailwind from the macro backdrop introduce real fade risk. No strong reversal signals are present either. On balance, the setup is borderline — modest downside momentum without a clear driver, mild macro support for the name, but enough time and intraday flow to sustain the move. Probability sits at the 0.5 threshold: take the trade given bounded risk, but without high conviction.
- !Jul 14, 9:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is down 1.66% today, a meaningful but not extreme move. The only headline is a generic Zacks industry outlook piece covering multiple healthcare distributors including Cardinal Health — no company-specific catalyst is evident, making this more likely flow/sector rotation than news-driven. The macro context shows a flattening yield curve (T10Y2Y 1.9σ below trend), which is modestly supportive of defensives like healthcare distributors, creating a mild headwind against further downside continuation. With 355 minutes remaining there is ample time for the move to extend, but the lack of a clear negative catalyst and the defensive sector tailwind from the macro backdrop introduce real fade risk. No strong reversal signals are present either. On balance, the setup is borderline — modest downside momentum without a clear driver, mild macro support for the name, but enough time and intraday flow to sustain the move. Probability sits at the 0.5 threshold: take the trade given bounded risk, but without high conviction.
- ?Jul 6, 11:26 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is down 1.71% with no attributable news catalyst, which is a moderate move but below the 2-5% threshold that would signal strong conviction flow. With 260 minutes remaining there is ample time for continuation, but several factors weigh against it: (1) No headlines to sustain narrative momentum — absent a catalyst, mid-session drifts in healthcare distributors like CAH often reflect sector rotation or index rebalancing that can mean-revert into the close. (2) The macro backdrop shows 10Y inflation expectations (T10YIE) running 1.6σ below trend at 2.23, which is modestly supportive of long-duration and defensive names like CAH rather than pressuring them further — this creates a mild headwind to continuation of the downside. (3) CAH as a healthcare distributor is relatively insulated from macro vol and tends to exhibit lower intraday trending behavior. (4) Without volume confirmation data, the move cannot be confirmed as institutionally driven. The setup does not clear the 0.5 threshold needed to trigger a short position — the macro context provides a mild mean-reversion lean, and the absence of a news driver in a typically low-beta name tips this marginally toward fade rather than continuation.
- !Jul 6, 11:26 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
CAH is down 1.71% with no attributable news catalyst, which is a moderate move but below the 2-5% threshold that would signal strong conviction flow. With 260 minutes remaining there is ample time for continuation, but several factors weigh against it: (1) No headlines to sustain narrative momentum — absent a catalyst, mid-session drifts in healthcare distributors like CAH often reflect sector rotation or index rebalancing that can mean-revert into the close. (2) The macro backdrop shows 10Y inflation expectations (T10YIE) running 1.6σ below trend at 2.23, which is modestly supportive of long-duration and defensive names like CAH rather than pressuring them further — this creates a mild headwind to continuation of the downside. (3) CAH as a healthcare distributor is relatively insulated from macro vol and tends to exhibit lower intraday trending behavior. (4) Without volume confirmation data, the move cannot be confirmed as institutionally driven. The setup does not clear the 0.5 threshold needed to trigger a short position — the macro context provides a mild mean-reversion lean, and the absence of a news driver in a typically low-beta name tips this marginally toward fade rather than continuation.
- !Jun 30, 9:18 AMsignal
options_momentum — insufficient_capital
- !Jun 30, 7:04 AMsignal
options_momentum — insufficient_capital
- !Jun 29, 5:46 PMsignal
options_momentum — insufficient_capital
- !Jun 29, 5:34 PMsignal
options_momentum — insufficient_capital
- !Jun 29, 5:21 PMsignal
options_momentum — insufficient_capital
- !Jun 29, 4:50 PMsignal
options_momentum — insufficient_capital
- !Jun 29, 9:51 AMsignal
options_momentum — insufficient_capital
- !Jun 29, 7:06 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 12:49 PMsignal
options_momentum — insufficient_capital
- !Jun 26, 11:51 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 10:48 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 10:35 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 10:21 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 9:50 AMsignal
options_momentum — insufficient_capital
- !Jun 26, 9:35 AMsignal
options_momentum — insufficient_capital
- ?Jun 18, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is down 2.58% intraday, a meaningful move suggesting real selling pressure. The single headline referencing 'headwinds' is directionally consistent with the move but provides limited additional catalyst. Macro context shows a flat/slightly positive yield curve (T10Y2Y at 0.29, below trend), which mildly favors defensives like healthcare distributors — this could act as a modest headwind to further downside but is not a strong reversal signal. With 275 minutes remaining there is ample time for continuation, but also for mean-reversion. No strong technical reversal pattern is described. The setup is ordinary momentum with no compelling reason to expect a fade, but also lacks the clear volume/sector confirmation needed for high conviction. Assigning a modest continuation probability just above the threshold.
- !Jun 18, 11:10 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
CAH is down 2.58% intraday, a meaningful move suggesting real selling pressure. The single headline referencing 'headwinds' is directionally consistent with the move but provides limited additional catalyst. Macro context shows a flat/slightly positive yield curve (T10Y2Y at 0.29, below trend), which mildly favors defensives like healthcare distributors — this could act as a modest headwind to further downside but is not a strong reversal signal. With 275 minutes remaining there is ample time for continuation, but also for mean-reversion. No strong technical reversal pattern is described. The setup is ordinary momentum with no compelling reason to expect a fade, but also lacks the clear volume/sector confirmation needed for high conviction. Assigning a modest continuation probability just above the threshold.
- ▣Jun 14, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $226.38 (+$32.00)
Target hit (partial-rounded-to-full): close $226.38 ≥ target $217.77
- ▣Jun 14, 8:00 PMjournalmanual
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $222.47 (+$28.09)
Staged exit (1/2.0): close $223.85 ≥ target $217.77. Selling 1/2 sh, trailing remainder.
- ▣Jun 11, 8:00 PMjournalmanual
Agent 5 — Dip Buyer (Evolving) closed long 1 @ $217.49 (+$23.11)
Staged exit (1/2.0): close $221.16 ≥ target $217.77. Selling 1/3 sh, trailing remainder.
- ✓Jun 10, 8:31 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] The PV path shows a textbook cluster_break_up setup. From 2026-05-21 through 2026-06-05, CAH's scatter dots clustered tightly in the $194–$202 price band on declining or subdued volume (1.2M–2.3M), forming a clear low-energy consolidation base. The break begins on 2026-06-09 when the close surged to $212.67 on 3.2M volume — the highest up-day volume in over two weeks — and is confirmed on 2026-06-10 (today) with a follow-through close at $216.30 on 3.4M volume (z-score +1.55 vs. trailing 20-day mean of 2.3M). Two consecutive expanding-volume up-days clearing the cluster by ~7% satisfies SIR's multi-session confirmation requirement; the path has moved decisively up-and-right out of the base, signaling fresh demand absorbing the float rather than a single-bar anomaly. Risks: A reversal back below the cluster ceiling (~$202) on elevated volume would signal a failed breakout and distribution, invalidating the bullish read entirely. Additionally, the macro backdrop — T10Y2Y at 0.4 (2.1σ below trend) flagging a bear-flattening yield curve — poses a sector-level headwind for Health Care defensives if risk-off rotation accelerates and compresses multiples.
- ▣Jun 10, 8:00 PMjournaltarget
Agent 5 — Dip Buyer (Evolving) closed long 3 @ $221.16 (+$80.34)
Staged exit (1/2.0): close $221.16 ≥ target $217.77. Selling 3/6 sh, trailing remainder.
- ▣Jun 10, 8:00 PMjournaltarget
Agent 8 — Dip Buyer (Peer-Aware) closed long 5 @ $221.16 (+$100.08)
Staged exit (1/2.0): close $221.16 ≥ target $217.77. Selling 5/10 sh, trailing remainder.
- ▢Jun 10, 8:00 PMjournal
Agent 20 — SIR Price/Volume opened long 9 @ $216.30
- ?Jun 10, 11:26 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 2.83% intraday with no attributable headline, suggesting institutional flow rather than news-driven speculation. With 260 minutes remaining (well over 4 hours), there is ample time for continuation into the close. However, the macro context is a mild headwind: T10Y2Y at 2.1σ below trend favors defensive sectors in a bear-flattening environment, and CAH as a healthcare distributor (defensive) could see some rotation pressure if the yield curve dynamic is actively being traded today. No reversal signal is evident from the data provided — the move appears to be holding. Absence of news is not a disqualifier; the 2.83% move itself represents meaningful conviction. With no clear fade catalyst and time remaining sufficient for trend continuation, a modest continuation probability above 0.5 is appropriate, though the muted macro tailwind and lack of confirmatory volume data prevent a higher conviction read.
- ✓Jun 10, 9:36 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.15% unrealized. Added 3 sh @ $215.01 ($645.04). Position now 10 sh @ weighted avg $201.14.
- ?Jun 5, 3:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.77% intraday, a modest but real move. However, with only 15 minutes remaining until the forced close, there is very little time for additional upside to develop toward the +3% target. The macro context shows a flattening yield curve (T10Y2Y 1.9σ below trend), which is a mild headwind for defensives like healthcare distributors in a bear-flattening environment. No news catalyst is present to sustain buying pressure. With the extreme time constraint, even a genuine momentum setup has insufficient runway to reach the profit target before the 3:45 PM ET cutoff, and late-session profit-taking is a common pattern for stocks already up ~2% without a clear catalyst. The risk/reward of entering with 15 minutes left is unfavorable — the probability of meaningful continuation in this window falls below the 0.5 threshold.
- ?Jun 5, 9:20 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 3.01% intraday with no headline catalyst visible, suggesting institutional flow or sector rotation rather than a news spike that might fade quickly. With 385 minutes remaining (well over 6 hours — this appears to be an early-session read), there is ample time for continuation. However, the macro context is a mild headwind: the T10Y2Y spread printing 1.9σ below trend favors defensives in a bear-flattening scenario, and CAH (healthcare distribution) is a defensive name that could see some of today's move attributed to defensive rotation — which may already be largely priced in at this intraday level. The absence of news means we cannot confirm a fundamental catalyst, but per framework this does not disqualify the setup. The 3% move represents real size and conviction. No reversal pattern or fade signal is evident. With no strong reason to expect a fade but also no clear continuation catalyst beyond price momentum, this sits in the ordinary momentum band. Assigning 0.54 — lean long but not high conviction.
- ?Jun 4, 2:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 2.82% intraday, a meaningful move suggesting real institutional flow with conviction. No directly attributable headline for CAH today (the Kinaxis headline is irrelevant), but absence of news does not disqualify continuation. Macro context is mildly cautious — T10Y2Y at 2.1σ below trend favors defensives in a bear-flattening regime, and CAH (healthcare distribution) has some defensive characteristics that could be supportive rather than headwind. However, with 105 minutes remaining, the move is already well-developed at nearly 3% and approaching the +3% profit target zone (~$201.74 from prior close), which may invite profit-taking and natural resistance. The macro yield curve read is not a strong tailwind for this specific name. Overall, no clear reason to fade — momentum bias holds — but limited upside remaining to the target and moderate time left temper conviction. Assigning a modest continuation probability just above threshold.
- ▣May 28, 8:00 PMjournalstop
options_momentum closed long 100 @ $5.35 (-$260.20)
Stop: premium $5.35 ≤ trailing floor $6.38 (peak $8.51 × 0.75)
- ✓May 20, 6:00 PMdecisionacted
options_momentum — decide: buy
CALL on CAH — 5-day return 6.93% with close above 20-day MA ($194.92). IV 34.9%. Sized 1 contract(s) at $7.95 premium.
- ✓May 20, 7:00 AMdecisionacted
options_momentum — decide: buy
CALL on CAH — 5-day return 9.76% with close above 20-day MA ($194.98). IV 35.6%. Sized 1 contract(s) at $8.71 premium.
- ▢May 19, 8:00 PMjournal
options_momentum opened long 100 @ $7.95
- ?May 19, 2:21 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.52% today, a modest but real move suggesting some directional flow. No headlines are available to explain the move, which is common — absence of news is not disqualifying. However, several factors temper conviction: (1) The move is only 1.52%, below the 2-5% threshold that would signal strong institutional conviction or a catalyst-driven run. (2) With 85 minutes remaining until the 3:45 PM cutoff, there is time for continuation but also meaningful risk of afternoon fade, particularly in a low-news environment where the initial push may have exhausted near-term buyers. (3) The macro context shows elevated 10-year inflation expectations (T10YIE at 2.4σ above trend), which pressures long-duration sensitive sectors; CAH as a healthcare distributor is not highly duration-sensitive, so this is a modest headwind rather than a direct negative. (4) No reversal signals or fade patterns are evident from the data provided. On balance, the modest upward momentum with no counter-thesis warrants a slight lean toward continuation per the system's borderline-favor-action rule, but this is a low-conviction read.
- ?May 19, 12:50 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.67% today, a modest but real move suggesting some buying conviction. No news headlines are available to explain the move, which is common and not disqualifying. The macro context shows elevated 10-year inflation expectations (T10YIE at 2.4σ above trend), which is a mild headwind for long-duration sensitive sectors, but CAH as a healthcare distributor is relatively rate-insensitive and not in the primary crosshairs of that dynamic. With 175 minutes remaining there is meaningful time for continuation, but the move is below the 2% threshold where momentum becomes strongly self-reinforcing. No reversal signals or thin-volume flags are evident from the data provided. Overall this is a borderline read — modest momentum, neutral-to-mild macro backdrop, ample time — that resolves just above the 0.5 threshold per the system's bias toward action when no clear fade reason exists.
- ?May 19, 11:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CAH is up 1.68% with no attributable headline, suggesting quiet institutional flow rather than a news-driven spike that might fade. The move is below the 2-5% threshold for strong conviction reads, so it's a modest drift upward. Macro context shows elevated 10Y inflation expectations (2.4σ above trend), which is a mild headwind for long-duration sensitive sectors, but CAH as a healthcare distributor is relatively insensitive to duration dynamics — this macro factor is largely neutral here. With 285 minutes remaining there is ample time for continuation or mean reversion. No reversal signal or fade pattern is evident from the data provided. The absence of news does not argue against continuation. Base case is mild upward drift persists into close, but conviction is low given the modest move magnitude and no catalytic driver. Probability just above the 0.5 threshold reflecting ordinary momentum with no strong reason to fade.
- ✓May 19, 7:01 AMdecisionacted
options_momentum — decide: buy
CALL on CAH — 5-day return 9.46% with close above 20-day MA ($195.21). IV 37.0%. Sized 1 contract(s) at $8.86 premium.
- ✓May 18, 9:25 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
CAH's 10.4% drop from its 30-day high appears largely sector-driven rather than company-specific — Health Care (XLV) ranks 10th of 11 sectors by 30-day relative strength with a -13.87pt underperformance vs. SPY, suggesting the dip reflects sector-wide rotation pressure rather than idiosyncratic impairment. A recent news headline references a higher dividend and raised guidance, which is a modest positive fundamental signal indicating management confidence in the business. Options flow shows a bullish-leaning P/C ratio of 0.70 with meaningful call volume (2,373 vs. 1,660 puts), suggesting more call interest than put interest on the dip. Earnings are 84 days away, well outside the binary-event caution window, removing that key risk factor.
- ?May 18, 8:54 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no recent news headlines or SEC filings available, there is no evidence of fundamental deterioration at Cardinal Health — the drop appears likely attributable to macro-driven sector rotation or broader market pressure rather than company-specific issues. The elevated 5-year inflation breakeven (2.7, ~2.5σ above trend) suggests a risk-off or rate-anxiety environment that could weigh on defensive healthcare distributors with thin margins. CAH is a large, established pharmaceutical distributor with historically stable cash flows, so the business itself appears sound absent contrary evidence.
- ▢May 17, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 5 @ $201.14
- ▢May 17, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 5 @ $201.14
- ?May 16, 6:35 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.08 cash available; close=$195.20.
- ?May 16, 10:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH is down 10.4% from its 30-day high at $195.20, but the evidence base is nearly empty — no recent news, no SEC filings, no insider activity, and no options flow data to diagnose the cause of the decline or signal informed buying interest. Without understanding why the stock dropped, buying into the dip carries unquantified idiosyncratic risk. The macro backdrop is mixed but not supportive: today's broad market is under pressure (SPY -1.20%, IWM -2.41%), the 10Y yield at 4.47% is near the structural headwind threshold, and the 5Y breakeven inflation at 2.7% (2.5σ above trend) introduces macro uncertainty that weighs on rate-sensitive healthcare distributors. VIX at the 50th percentile is neutral — not elevated enough to signal a capitulation bottom, but not benign either. Earnings are 86 days out, which removes binary event risk from the 90-day window. However, without any confirming signals (no insider buys, no unusual call flow, no sector-underperformance context to explain a sympathy move), the drop looks unexplained and potentially fundamental. The absence of data is itself a risk factor — it prevents conviction in either direction but biases toward caution given the conservative framework.
- ?May 16, 9:00 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no recent news headlines or SEC filings available, there is no evidence of fundamental deterioration at Cardinal Health — the drop appears likely attributable to macro-driven sector rotation or broader market pressure rather than company-specific issues. The elevated 5-year inflation breakeven (2.7, ~2.5σ above trend) suggests a risk-off or rate-anxiety environment that could weigh on defensive healthcare distributors with thin margins. CAH is a large, established pharmaceutical distributor with historically stable cash flows, so the business itself appears sound absent contrary evidence.
- ?May 16, 8:58 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 15, 6:37 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 15, 6:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 15, 6:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 15, 6:15 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 15, 3:38 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ✓May 15, 9:01 AMdecisionacted
Agent 7 — Day Trader — decide: buy
CAH is up 4.31% intraday with no attributable headline, suggesting institutional flow or a catalyst not yet widely reported. A move of this magnitude reflects real conviction and size. However, several factors temper enthusiasm: (1) no news anchor means the move could be driven by a single large order that has now completed, increasing fade risk; (2) the macro context shows elevated 5Y breakeven inflation (2.7, 2.5σ above trend), which is not directly supportive of healthcare/distribution names like CAH; (3) with 405 minutes remaining (effectively a full afternoon session), there is ample time for either continuation or reversal, but also for profit-taking after a sharp gap-up move. The absence of a clear catalyst and the size of the move (near the upper bound of a single-day range) suggest some mean-reversion pressure is possible. That said, the system's asymmetric payoff structure (tight -1.5% stop vs. +3% target) and the default bias toward taking borderline trades push this to a modest continuation probability above 0.5. No reversal pattern is evident, and no sector headwind is directly applicable.
- ✓May 14, 9:36 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
CAH (Cardinal Health) is a large-cap healthcare distributor with durable cash flows and a defensively positioned business model, suggesting the 10.7% pullback from its 30-day high is more likely technical or sector-rotation-driven than fundamental deterioration — especially given the absence of any negative headlines or adverse SEC filings in the window. Today's broad market is constructively positive (SPY +0.79%, VXX -2.54%), which supports risk-on sentiment that could help a healthcare name recover. However, the elevated 5-year breakeven inflation reading (2.7, 2.5σ above trend) introduces margin and cost-of-goods uncertainty for a low-margin distribution business like CAH.
- ✓May 14, 9:35 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
CAH (Cardinal Health) is a large-cap healthcare distributor with relatively stable, defensive cash flows and no recent negative news or SEC filings visible in the window to explain the 10.7% pullback from its 30-day high. Today's broad market is firmly positive (SPY +0.79%, QQQ +0.71%, VXX -2.54%), suggesting the drop is not macro-driven panic but likely reflects idiosyncratic selling pressure or sector rotation, which historically tends to mean-revert for fundamentally sound names. The elevated 5-year inflation breakeven (T5YIE at 2.7, 2.5σ above trend) is a mild headwind for defensive healthcare distributors but not a disqualifying factor.
- ?May 14, 9:34 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no headlines or SEC filings in the window, the ~10.7% pullback from the 30-day high appears driven by macro/sector rotation rather than company-specific deterioration. CAH (Cardinal Health) is a large-cap healthcare distributor with relatively stable cash flows and defensive characteristics, suggesting the business fundamentals are likely intact. However, the elevated 5-year inflation breakeven (2.7, 2.5σ above trend) signals a risk-off macro environment that could continue to pressure rate-sensitive and lower-margin distribution businesses, limiting near-term upside.
- ?May 14, 9:34 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 14, 9:33 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no headlines or SEC filings in the window, the ~10.7% pullback from the 30-day high appears driven by macro/sector rotation rather than company-specific deterioration. CAH (Cardinal Health) is a large-cap healthcare distributor with relatively stable cash flows and defensive characteristics, suggesting the business fundamentals are likely intact. However, the elevated 5-year inflation breakeven (2.7, 2.5σ above trend) signals a risk-off macro environment that could continue to pressure rate-sensitive and lower-margin distribution businesses, limiting near-term upside.
- ?May 14, 9:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ?May 14, 9:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no headlines or SEC filings in the window, the ~10.7% pullback from the 30-day high appears driven by macro/sector rotation rather than company-specific deterioration. CAH (Cardinal Health) is a large-cap healthcare distributor with relatively stable cash flows and defensive characteristics, suggesting the business fundamentals are likely intact. However, the elevated 5-year inflation breakeven (2.7, 2.5σ above trend) signals a risk-off macro environment that could continue to pressure rate-sensitive and lower-margin distribution businesses, limiting near-term upside.
- ?May 14, 9:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CAH (Cardinal Health) is a large-cap healthcare distribution company with generally stable fundamentals, but the 10.7% drop from its 30-day high is notable given the absence of any news headlines or recent SEC filings to explain it — this suggests either sector rotation, macro-driven selling, or a catalyst that predates the 30-day window. Today's broad-market tone is constructively bullish (SPY +0.79%, VXX -2.54%), which is modestly supportive of a recovery, but the idiosyncratic nature of a ~11% drawdown without visible news is a yellow flag. The elevated 5-year inflation breakeven (T5YIE at 2.5σ above trend) adds margin pressure uncertainty for a low-margin distributor like CAH.
- ▢May 14, 8:00 PMjournal
Agent 7 — Day Trader opened long 10 @ $194.38
- ▣May 14, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 10 @ $196.08 (+$17.00)
EOD forced close — day trader never carries overnight
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 3 @ $194.38
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.38
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.38
- ▢May 14, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 1 @ $194.38